Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: tommysdad who wrote (1564)	2/11/1999 11:17:00 PM
From: Mao II	Respond to of 2135

tommysdad: Your post makes good sense on all scores. I would say, however, that there is more to BMY's walking away from angiostatin. What kind of relationship did ENMD have with BMY anyway? There have been some news reports suggesting that a key ENMD backer at BMY left the company and that the relationship deteriorated quickly thereafter. There have been other reports that suggested BMY wanted in on an endostatin deal, but ENMD said, No dice, angering BMY exex. Did BMY have any signal from NCI about the endostatin test results? It's seems very odd that BMY walked away one day before the NCI results become public. M2